450

ENDOMETRIAL CANCER IN CLINICAL PRACTICE: THE EXPERIENCE OF AN ONCOLOGICAL CENTER

R Fontes*, J Rodrigues, C Oliveira, M Peixoto, F Pereira, J Cunha, C Portela, A Marques, R Naboço, L Queiroz. *Portugal, Medical Oncology, Portugal*

10.1136/ijgc-2021-ESGO.148

Introduction/Background* Endometrial cancer is the fourth most common malignancy among women and the most frequent gynecological cancer in developed countries. Generally it is associated with a favourable prognosis mainly because most cases are diagnosed at an early stage. This work aims to evaluate the real-life data of an oncological center.

Methodology Retrospective analysis of data from patients diagnosed and treated in our institution, from January 2009 to December 2019.

Result(s)* During this period, 217 patients were diagnosed with endometrial cancer, with a median age at diagnosis of 67 years. Regarding clinical staging, the majority of them were in early stage disease – FIGO I/II (69%, n=149) and mainly endometrioid histological subtype (71%. n=154).

High-risk endometrial cancer was seen in 41,9% of the patients (n=91). From these, 36,3% (n=33) were treated with adjuvant radiotherapy, with or without brachytherapy, and 56% (n=51) also received chemotherapy (carboplatin + paclitaxel) before radiation treatment. Recurrence occurred in 23 patients, mainly FIGO stage IIIC1.

Overall, relapse was detected in 36 patients (16,6%) – 15 patients with loco-regional disease and 21 with distant metastasis – with a median progression free survival of 12 months. Histology was found to be the major risk factor (p=0,05) for recurrence.

To date, the number of deaths was 64 (29,5%), but 15 patients died from other causes. In multivariate analysis, the independent prognostic factors were histology (p=0,01), FIGO stage (p=0,05) and lymphovascular involvement (p=0,00), with the last one being the most significant (B=1,077). Overall survival was 82,3% and 72,2% at 2 and 5 years, respectively.

From the 217 patients 61,8% (n=133) are under follow-up, showing no signs of recurrence.

Conclusion* Although endometrial cancer is generally diagnosed at an early stage, differences in patient characteristics and histopathological features of the disease impact on both prognosis and treatment approach. Over the past few decades, several studies have demonstrated the prognostic importance of different parameters including histological subtype and grade, stage of disease and lymphovascular involvement. Taking into account the advances in the oncology setting, the future will probably be focused on the molecular profile of endometrial cancer.

453

EXTERNAL VALIDATION OF THE NORWICH DEFAB SCORE FOR UP-FRONT PREDICTION OF ENDOMETRIAL CANCER

J Davies, K Hartshorn, L Honeyman, S Kolhe, A Phillips. *Derby Gynaecological Cancer Centre, derby, UK*

10.1136/ijgc-2021-ESGO.149

Introduction/Background* The DEFAB score combines clinical data and patient characteristics such as Age, endometrial thickness, diabetes, BMI and bleeding characteristics to calculate the risk of endometrial cancer causing PMB. It was based on 3047 patients cared for between 2006 and 2009. Inclusion was all women presenting with PMB. The original authors proposed a cut off score of 3 – whereby a score of ≤ 2 is managed based on ultrasound assessment of endometrial thickness; whereas a score of ≥ 3 was additionally investigated with endometrial biopsy regardless of any ultrasound findings, and proceeded to hysteroscopy if this biopsy is negative.

Methodology We compared the baseline characteristics of our cohort to the original internal validation study and retrospectively applied the DEFAB score to our patient group to determine how it performed.

Result(s)* Mean age was 61 (50-95) years, BMI was 30.7 (25-36) and 30.2 (25-36) in cancer and non-cancer patients. Diabetes was present in 20 (20.6%) and 93 (9.7%) cancer and non-cancer patients. The bleeding pattern was recurrent in 39 (40%), and 309 (32.2%) in cancer and non-cancer patients.

42 cancer patients had a DEFAB score of ≤ 2 , of whom 41 met the endometrial thickness criteria and went on to have a cancer diagnosed. There was one cancer found in a patient who the DEFAB protocol would have discharged without diagnosis, a false negative rate of 2.4%.

The incidence of cancer in patients with a DEFAB score of > 3 (n=457), was 58 (12.7%). The sensitivity of the DEFAB & ET thresholding protocol was 98.7% if the cut-off DEFAB score of 3 is used, with a specificity of 60.1%.

Conclusion* The DEFAB score performs well at the proposed cutoff in our cohort.

457

DEEP INFILTRATING ENDOMETRIOSIS: NEOPLASM OR BENIGN CONDITION?

K Grammatikakis*, A Theodoropoulou, E Halkia, K Patsouras. *Tzaneio Prefecture General Hospital of Piraeus, Piraeus, Greece*

10.1136/ijgc-2021-ESGO.150

Introduction/Background* Deep infiltrating endometriosis is an interesting rare subtype of endometriosis which was recently subjected to genomic evaluation. There are three major subtypes of endometriosis up to date, ovarian endometrioma (OMA), superficial peritoneal endometriosis (SPE), and deep infiltrating endometriosis (DIE). Deep endometriosis has the particular nature to locally invade surrounding structures such as bowel, bladder and ureter) but rarely metastasizes. The present knowledge indicates that hormonal function and immunological factors, such as peritoneal macrophages, natural killer cells, and lymphocytes, are sensibly altered in DIE. Invasive mechanisms are more expressed in DIE in comparison to the OMA and SPE. Correlated with the increased invasiveness are the data on very high expression of neuroangiogenesis genes in DIE.

Methodology Our aim was to evaluate the latest data that can correlate the microenvironment of deep infiltrating endometriosis (DIE) with the one of endometrial cancer, discuss the possibility that perhaps even the deep-infiltrating subtype of

endometriosis, which demonstrates unequivocal invasion of surrounding tissues, may be more appropriately considered a neoplasm than a benign condition and review the latest treatment algorithm

Result(s)* Three recent studies demonstrated commonly occurring epithelial mutations in PIK3CA and ARID1A in endometriosis that are uniquely shared with clear cell and endometrioid ovarian epithelial cancers. The cytochrome P450 enzyme CYP1B1 convert estrogens to 4-hydroxy-catechol estrogens and, eventually, their depurinating quinone metabolites that cause DNA adducts leading to mutagenic apurinic sites. This would lead to accumulation of additional mutations during epithelial cell division. The estimated rate of malignant transformation for endometriosis is close to 1%, and recent results suggest that the presence of driver mutations alone is neither sufficient to drive the transformation of endometriosis nor indicative of likely progression to cancer.

Conclusion* : Massive concentrations of estrogen in the ovary may exert a direct genotoxic effect on DNA of ectopic endometrial (endometriotic) epithelial cells. Endometriosis is widely considered to be a benign disorder both clinically and a histopathologically. Well-known cancer-associated somatic mutations were found in the glandular epithelium of some deep infiltrating endometriosis lesions. These are exciting findings that share new light on all forms of endometriosis and their association with endometrial cancer.

462

EXPERIENCE IN SELECTIVE LYMPH NODE BIOPSY USING ICG IN ENDOMETRIAL CANCER

AF Rave Ramirez, D González García-Cano*, M Laseca Modrego, O Arencibia Sanchez, A Martín Martínez. *Complejo Hospitalario Universitario Insular Materno Infantil de Gran Canaria, Gynecologic Oncology, las palmas de gran canaria*

10.1136/ijgc-2021-ESGO.151

Introduction/Background* The objective of this study is to describe the results of patients with endometrial adenocarcinoma in early stages, which have undergone a selective sentinel lymphatic node biopsy (SLNB).

Methodology Retrospective observational descriptive study of patients with endometrial cancer treated by robotic surgery with Da Vinci Xi who underwent SLNB by Indocyanine green staining with ultrastratification using 5 sections separated by 200 microns. Study conducted from April 2019 to June 2020. We included 24 patients with early stages Endometrial adenocarcinoma. The technique for performing BSGC was by diluting 25 mg oc ICG in 5 ml of physiological serum and then 1 ml of this dilution in another 10 ml of serum. Subsequently we administered 1 ml of this solution in the cervix at 3 and 9 o'clock points by introducing a 21G needle, 1 cm deep into the cervix

Result(s)* The sample had a mean age of 61.3 years and a mean BMI of 28.6. In 2 of the cases (8%) the SN were positive even presenting myometrial infiltration <50% and in three of the cases (12.5%) the SN were not identified. SLNs were located in 98% of cases (n: 23) at the level of the obturator fossa and just in one case (2%) at the level of the external iliac artery and vein.

Conclusion* SLNB is an effective technique to assess lymphatic involvement due to adenocarcinoma of the endometrium in early stages.

466

PREOPERATIVE CA125 SIGNIFICANTLY IMPROVES RISK STRATIFICATION IN HIGH-GRADE ENDOMETRIAL CANCER

¹M Lombaers*, ¹K Cornel, ^{2,3}N Visser, ^{4,5}F Amant, ⁶P Bronsers, ⁷P Geomini, ^{8,9}A Gil-Moreno, ¹⁰D Van Hamont, ¹¹J Huvila, ^{12,13}C Krakstad, ¹⁴M Koskas, ¹⁵G Mancebo Moreno, ¹⁶X Matias-Guiu, ¹⁷B Pijlman, ¹⁸C Vos, ¹⁹V Weinberger, ²⁰M Snijders, ^{12,21}I Haldorsen, ²²C Reijnen, ^{1,23}J Pijnenborg. ¹Radboud University Medical Center, Dept. Obstetrics and Gynecology, Nijmegen, Netherlands; ²Radboud University Medical Center, Dept. Pathology, Nijmegen, Netherlands; ³Stichting PAMM, Dept. Pathology, Eindhoven, Netherlands; ⁴KU Leuven, Dept. Oncology, Leuven, Belgium; ⁵The Netherlands Cancer Institute (NKI), Center for Gynecologic Oncology, Amsterdam, Netherlands; ⁶University Medical Center, Institute of Pathology, Freiburg, Germany; ⁷Maxima Medical Center, Dept. Obstetrics and Gynecology, Veldhoven, Netherlands; ⁸Vall d'Hebron Institut de Recerca, Biomedical Research Group in Gynecology, Barcelona, Spain; ⁹Vall d'Hebron University Hospital, Dept. Gynecology, Barcelona, Spain; ¹⁰Amphia Hospital, Dept. Obstetrics and Gynecology, Breda, Netherlands; ¹¹University of Turku, Dept. Pathology, Turku, Finland; ¹²University of Bergen, Clinical Science, Bergen, Norway; ¹³Haukeland University Hospital, Dept. Obstetrics and Gynecology, Norway; ¹⁴Bichat-Claude Bernard Hospital, Dept. Obstetrics and Gynecology, Paris, France; ¹⁵Hospital del Mar, Dept. Obstetrics and Gynecology, Barcelona, Spain; ¹⁶Hospital Universitari Arnau de Vilanova, Pathology and Molecular Genetics and Research Laboratory, Lleida, Spain; ¹⁷Jeroen Bosch Hospital, Dept. Obstetrics and Gynecology, 's-Hertogenbosch, Netherlands; ¹⁸Elisabeth-TweeSteden Hospital, Dept. Obstetrics and Gynecology, Tilburg, Netherlands; ¹⁹University Hospital Brno, Dept. Obstetrics and Gynecology, Brno-Bohunice, Czech Republic; ²⁰Canisius Wilhelmina Hospital, Dept. Obstetrics and Gynecology, Nijmegen, Netherlands; ²¹Haukeland University Hospital, Mohn Medical Imaging and Visualization Centre, Department of Radiology, Norway; ²²Radboud University Medical Center, Dept. Radiation Oncology, Nijmegen, Netherlands; ²³Radboud Institute For Health Sciences, Nijmegen, Netherlands

10.1136/ijgc-2021-ESGO.152

Introduction/Background* Patients with high-grade endometrial carcinoma (EC) have an increased risk of lymph node metastasis (LNM). Preoperative serum CA125 and imaging findings have been incorporated in multiple risk stratification models to predict LNM and advanced disease in EC and are widely used in clinical practice. However, data on their predictive value in high-grade EC are limited. We therefore aim to determine the predictive value of CA125 combined with preoperative computed tomography (CT) imaging in high-grade EC for LNM.

Methodology Retrospective multicentre cohort study including patients (n=334) with preoperative high-grade EC and available CA125. Clinical data including imaging results, primary surgical treatment and final International Federation of Gynecology and Obstetrics (FIGO) stage were recorded. CA125 was considered elevated at >35 IU/L.

Result(s)* Patients with high-grade EC (n=334) and elevated CA125 more often presented with advanced FIGO stage (III-IV), 64.2% (95/148) versus 18.8% (35/186) in patients

Abstract 466 Table 1 CA125 and CT results in relation to lymph node metastasis (N1) in patients who underwent surgical staging

	Total n=148	N0 n=107	N1 n=41
CA125 <35 U/mL, imaging not suspect for LNM	89	77 [86.5%]	12 [13.5%]
CA125 >35 U/mL, imaging not suspect for LNM	31	17 [54.8%]	14 [45.2%]
CA125 <35 U/mL, imaging suspect for LNM	9	8 [88.9%]	1 [11.1%]
CA125 >35 U/mL, imaging suspect for LNM	19	5 [26.3%]	14 [73.7%]